Journals / Ortadoğu Tıp Dergisi / 2012 / Cilt: 4 - Sayı: 1

Current treatment approaches for Klatskin tumors

Klatskin tümörlerinde güncel tedavi yaklaşımları

Pages
33–38
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This study aimed to emphasize the current treatment approaches for hilar cholangiocarcinoma in the light of literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hilar cholangiocarcinoma, is a relatively rare tumor arising from the bile ducts, was first described by Klatskin in 1965.
📊
Key Findings & Data:If 30% of the liver is drained jaundice can be relieved, but the presence of undrained bile ducts may result in pruritus and a continued risk of cholangitis and hepatic abscess.
💡
Conclusion & Impact:This study aimed to emphasize the current treatment approaches for hilar cholangiocarcinoma in the light of literature.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Hilar cholangiocarcinoma, is a relatively rare tumor arising from the bile ducts, was first described by Klatskin in 1965. It usually ocurs in adults in their sixth decade of life and there is slight male predominance. It is most frequently located in the confluence of the hepatic ducts, where it is called hilar cholangiocarcinoma or Klatskin tumor. The etiology of hilar cholangiocarcinoma remains unknown but there are predisposing conditions and environmental risk factors such as primary sclerosing cholangitis, Caroli disease, bile duct malformations, industrial toxins and parasitic infections. If 30% of the liver is drained jaundice can be relieved, but the presence of undrained bile ducts may result in pruritus and a continued risk of cholangitis and hepatic abscess. This study aimed to emphasize the current treatment approaches for hilar cholangiocarcinoma in the light of literature.

Özet

Hiler kolanjiokarsinom ilk olarak 1965 yılında Klatskin tarafından tanımlanmış, safra yolları epitelinden kaynaklanan nispeten nadir görülen bir tümördür. Kolanjiokarsinom genellikle yaşamın 6. dekadında ve erkeklerde biraz daha sıklıkla rastlanmaktadır. Klatskin yada Kolanjiokarsinomların etyolojisi tam olarak bilinmemekte ancak endüstriyel toksinler, parazitik infeksiyonlar, safra kanalı malformasyonları, caroli hastalığı, primer sklerozan kolanjit gibi predispozan ve çevresel faktörlerin etyolojide rol oynadığı düşünülmektedir. Hilar kolanjiokarsinomlarda karaciğerdeki safranın %30’unun drene olabilmesi halinde sarılık görülmeyebilir ancak bu drenaj sağlanmadığı takdirde kaşıntı, kolanjit ve hepatik apse oluşumu gibi sonuçlar ortaya çıkabilmektedir. Bu çalışmadaki amaç; hiler kolanjiokarsinomun cerrahi tedavisindeki ilerlemeleri literatür eşliğinde vurgulamaktır.

🔖

Cite This Article

KILIÇ, M., COŞKUN, A., BULUŞ, H., YAVUZ, A., MORKAVUK, B., AKKOCA, M. (2022). Current treatment approaches for Klatskin tumors. Ortadoğu Tıp Dergisi, Cilt: 4 - Sayı: 1, 33–38. https://ajindex.com/articles/585993

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Altemeier WA, Gall EA, Zinninger MM, Hoxworth P1. Sclerosing carcinoma of the major intrahepatic bile ducts. Arch Surg 1957
  2. Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features. Am J Med 1965
  3. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005
  4. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008
  5. Brandsaeter B, Isoniemi H, Broomé U, et al: Liver transplantation for primary sclerosing cholangitis
  6. predictors and consequences of hepatobiliary malignancy. J Hepatol 2004
  7. 815–822. 6.Flanigan DP: Biliary carcinoma associated with biliary cysts. Cancer 1977 Aug
  8. 40(2):880–883. 7.Yamamoto S, Kubo S, Hai S, et al: Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci 2004
  9. 592–595. 8.Vogl T.J.,Schwarz W.O.,Helter M. Staging of Klatskin Tumors (Hilar Cholangicarcinomas):comparison of MR cholangiography,MR imaging and ERCP.Eur Radiol (2006) 16:2317-2325. 9.Park HS, Lee JM, Choi JY, Lee MW, Kim HJ, Han JK, et al. Preoperative evaluation of bile duct cancer: MRI combined with MR cholangiopancreatography versus MDCT with direct cholangiography. AJR Am J Roentgenol 2008
  10. Nathan H, Aloia TA, Vauthey JN, Abdalla EK, Zhu AX, Schulick RD, et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 2009
  11. Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg 1992
  12. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti III A. Perihilar Bile Ducts. In: AJCC Cancer Staging Handbook. 7th ed. Chicago, IL: Springer
  13. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001
  14. Michelle L. DeOliveira, Richard D. Schulick, Yuji Nimura, Charles Rosen et al. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology 2011
  15. Jarnagin WR, Bowne W, Klimstra DS, Ben-Porat L, Roggin K et al. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg. 2005 May
  16. 241(5):703-12. 16. Li SQ, Liang LJ, Hua YP, et al. Long-term outcome and prognostic fact